Researchers are calling for participants to take part in a new research study investigating the effectiveness of intradermal administration of the existing TGA-approved Japanese encephalitis (JE) vaccine Imojev® compared with subcutaneous administration.

Healthy, non-pregnant individuals aged five years and older who do not currently meet NSW Health JE vaccine eligibility criteria are invited to participate in the study.

The Imojev® vaccine being administered in the study has been used extensively across the world for more than a decade and is proven to be both safe and effective. Enrolled individuals will be randomised in equal numbers to receive the JEV vaccine Imojev® either by intradermal injection – administered into the space between the two outer layers (epidermis and dermis) of the skin – or by subcutaneous injection – administered in the fatty tissue layer (subcutaneous layer) located between the skin and the muscle.

Participants will be actively followed up over 12 months to collect data on the immune response and safety profile of each vaccine delivery method. Findings will be published and will inform future vaccination policies and strategies in Australia.

---

Book your Japanese encephalitis vaccine appointment

If you are interested in participating, book an appointment at one of our upcoming study clinics below by calling 0428 963 193 (9am-5pm, Monday-Friday) or email SCHN-NCIRS-Research@health.nsw.gov.au

Bathurst Study Clinic
24–28 October 2023
8am–4pm

Ochre Medical Centre Bathurst
Building 1470 Charles Sturt University
Panorama Avenue
Bathurst, NSW, 2795

---

Your first appointment will take approximately two hours and all subsequent appointments will be 30 minutes or less.

Adult participant information sheet (.pdf) [493 KB]

Child (aged 5-11 years) participant information sheet (.pdf) [515 KB]

Young person (aged 12-17 years) participant information sheet (.pdf) [685 KB]

Parent/guardian participant information sheet (for participants aged 5-17 years) (.pdf) [506 KB]

If you have questions about the study or would like further information, please email Coordinating Principal Study Investigator, Professor Nick Wood at SCHN-NCIRS-Research@health.nsw.gov.au. 

This study is sponsored by The Sydney Children’s Hospitals Network and led by the National Centre for Immunisation Research and Surveillance and Murrumbidgee Local Health District, with funding support from NSW Health.